Sublingual immunotherapy for allergy-related asthma
Immunotherapy using sublingual tablets containing house dust mite allergen extended the interval until patients developed a moderate asthma exacerbation in a manufacturer-sponsored clinical trial reported online April 26 in JAMA.
However, patients’ scores on both the Asthma Control Questionnaire...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Asthma | Clinical Trials | Dermatology | Immunotherapy | Skin